A novel Cas9-targeted long-read assay for simultaneous detection of IDH1/2 mutations and clinically relevant MGMT methylation in fresh biopsies of diffuse glioma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-5960
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A novel Cas9-targeted long-read assay for simultaneous detection of IDH1/2 mutations and clinically relevant MGMT methylation in fresh biopsies of diffuse glioma ; volume:8 ; number:1 ; day:20 ; month:6 ; year:2020 ; pages:1-13 ; date:12.2020
Acta Neuropathologica Communications ; 8, Heft 1 (20.6.2020), 1-13, 12.2020
- Urheber
-
Wongsurawat, Thidathip
Jenjaroenpun, Piroon
Loose, Annick De
Alkam, Duah
Ussery, David W.
Nookaew, Intawat
Leung, Yuet-Kin
Ho, Shuk-Mei
Day, John D.
Rodriguez, Analiz
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40478-020-00963-0
- URN
-
urn:nbn:de:101:1-2020081720393765822446
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wongsurawat, Thidathip
- Jenjaroenpun, Piroon
- Loose, Annick De
- Alkam, Duah
- Ussery, David W.
- Nookaew, Intawat
- Leung, Yuet-Kin
- Ho, Shuk-Mei
- Day, John D.
- Rodriguez, Analiz
- SpringerLink (Online service)
Ähnliche Objekte (12)
Clinical impact of IDH1 mutations and MGMT methylation in adult glioblastoma
Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma : = Geschlechtsspezifische klinisch-pathologische Signifikanz neuer (Frizzled-7) sowie etablierter (MGMT, IDH1) Biomarker bei Glioblastomen
Amplification-free long-read sequencing reveals unforeseen CRISPR-Cas9 off-target activity
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
Cas9-directed long-read sequencing to resolve optical genome mapping findings in leukemia diagnostics
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma
MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study
Next generation configuration mgmt: Autonomous Databases
Charakterisierung eines monoklonalen, IDH1 R132H-mutationsspezifischen Antikörpers sowie die Herstellung eines zellkulturbasierten Tumormodells für IDH1-mutierte Gliome
Clinical impact of IDH1 mutations and MGMT methylation in adult glioblastoma
Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma : = Geschlechtsspezifische klinisch-pathologische Signifikanz neuer (Frizzled-7) sowie etablierter (MGMT, IDH1) Biomarker bei Glioblastomen
Amplification-free long-read sequencing reveals unforeseen CRISPR-Cas9 off-target activity
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
Cas9-directed long-read sequencing to resolve optical genome mapping findings in leukemia diagnostics
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma
MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study
Next generation configuration mgmt: Autonomous Databases
Charakterisierung eines monoklonalen, IDH1 R132H-mutationsspezifischen Antikörpers sowie die Herstellung eines zellkulturbasierten Tumormodells für IDH1-mutierte Gliome
Clinical impact of IDH1 mutations and MGMT methylation in adult glioblastoma
Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma : = Geschlechtsspezifische klinisch-pathologische Signifikanz neuer (Frizzled-7) sowie etablierter (MGMT, IDH1) Biomarker bei Glioblastomen
Amplification-free long-read sequencing reveals unforeseen CRISPR-Cas9 off-target activity
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
Cas9-directed long-read sequencing to resolve optical genome mapping findings in leukemia diagnostics
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma
MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study
Next generation configuration mgmt: Autonomous Databases